Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’

Sharing is Caring!

They will cure cancer when it is more profitable to cure it than treat it.

 

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.

“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.

www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html

See also  Civil War 2.0 Weather Report: It’s A Long Way To The Bottom
See also  They just Nailed Fauci for orchestrating Gain of Function research...

 

h/t FartfullyYours

1,890 views

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.